Disc Medicine (IRON) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$1.53
- Estimate
- -$1.71
- Surprise
- +10.6%
- Score today
- 5.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Disc Medicine (IRON) reported a narrower loss than forecast — adjusted EPS of -$1.53 against the -$1.71 estimate (a 10.6% beat on a still-unprofitable quarter).
Coverage in the report window
- HC Wainwright & Co. Maintains Buy on Disc Medicine, Raises Price Target to $127 — benzinga, 2026-11-06
- Disc Medicine Enters Sales Agreement With TD Cowen For Common Stock Offering; May Offer Common Stock Up To $189.93M Thro — benzinga, 2026-11-05
- Disc Medicine Reports Q3 2026 Financial Results and Operational Progress — fiscal.ai, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates IRON Sell at 5.5/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +10.6% surprise compares with a +8.2% four-quarter average.
What argues against it
- Concentration risk — Pipeline: bitopertin
- Quality below floor (1.6 < 4.0)
- Value-trap signals (2/5): High leverage (D/E 3.9), Material insider selling (6 sells, 0.16% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $78.47
- Price target
- $109.40
- Stop
- $72.98
- Upside to target
- +39.4%
- Reward-to-risk
- 2.6:1
Risk check: RSI 71 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
IRON at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.48B
- P/E (fwd)
- -11.5
- 52-week range
- $40.00–$99.50
- Off 52-week high
- 21.1%
- RSI (14)
- 71
- Volume vs avg
- 0.57×
- Score today
- 5.5/10